Accelerate drug development with synthetic clinical trials
At Biotrial, we leverage the power of In-Silico trials—also known as synthetic clinical trials—to simulate and predict the performance of drugs and medical interventions using advanced computational modeling. These digital simulations influence study designs and reduce development costs, improve patient safety, and speed up decision-making across clinical development.
In Silico trials use computer-simulated environments to model how a drug interacts with the human body. These simulations are built on biological, pharmacological, and clinical data, allowing researchers to forecast outcomes such as efficacy, safety, dosage response, and adverse effects—providing insights before actually running the trial.
In Silico trials are especially valuable when real-world or randomized clinical trials are limited by practical or ethical constraints, but they also hold strategic value for any trial where the team wishes to reduce risk and increase the confidence in choice of dose, in/ex criteria or choice of endpoints.Common use cases include:
These applications allow sponsors to gather critical data where traditional studies fall short.
Biotrial offers detailed trial simulations that model patient variability, dosing schedules, and treatment responses. This allows sponsors to:
When data is incomplete or limited (e.g., small populations, rare diseases), our models can simulate missing data points, enabling:
Reduce timelines by identifying potential failures early and adjusting trial designs in advance
Limit unnecessary recruitment, site costs, and amendments
Minimize exposure of patients to ineffective or harmful treatments
Our simulations meet industry standards and support regulatory expectations for model-informed drug development (MIDD)
